Literature DB >> 23242830

N-acetylcysteine administration is associated with reduced activation of NF-kB and preserves lung dendritic cells function in a zymosan-induced generalized inflammation model.

Hong-Wei Wang1, Wen Yang, Jiang-Yang Lu, Fei Li, Jun-Zhong Sun, Wen Zhang, Nan-Nan Guo, Lei Gao, Jia-Rui Kang.   

Abstract

PURPOSE: In severe sepsis, functional impairment and decreased numbers of dendritic cells (DCs) are essential reasons for immune function paralysis, secondary organ infection, and organ failure. We investigated the effects of N-acetylcysteine (NAC) administration on protecting lung DCs function in a zymosan-induced generalized inflammation (ZIGI) model.
METHODS: ZIGI was initiated in 80 Balb/c mice by intraperitoneal injection of zymosan (ZYM; 900 mg/kg). Mice were divided into 4 groups: (1) SHAM+Vehicle; (2) SHAM+NAC; (3) ZYM+Vehicle; and (4) ZYM+NAC. NAC (100 mg/kg) was administered at different time after ZYM injection. After 48 h, we assessed: lung tissue pathological changes; arterial blood gas values; purified lung DCs surface expressions of MHC-II/I-A(d) and co-stimulatory molecules CD80, CD83, and CD86; lung DCs mRNA levels of chemokine receptors CCR5 and CCR7; lung DCs apoptosis; lung DCs ultrastructure by transmission electron microscopy; lung DCs NF-kB transcription factor activity; and LPS-stimulated lung DCs in vitro production of IL-12 and IL-10 were examined.
RESULTS: NAC treatment resulted in: significant improvements in ZYM-induced lung tissue damage and impaired lung function; inhibited lung DCs ZYM-induced increased expression of MHC-II/I-A(d), CD83, and CD86, but not CD80; reduced lung DCs ZYM-induced CCR5 and CCR7 mRNA levels; suppressed ZYM-induced lung DCs apoptosis; ameliorated ZYM-induced lung DCs ultrastructural abnormalities; inhibited ZYM-induced lung DCs NF-κB activity; and enhanced lung DCs production of IL-12 and inhibited their production of IL-10.
CONCLUSIONS: Repeated injections of NAC during the early stage of severe sepsis effectively inhibited lung DCs activation and their apoptosis, which could preserve DCs function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242830     DOI: 10.1007/s10875-012-9852-3

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  32 in total

Review 1.  Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity.

Authors:  Y J Liu
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice.

Authors:  Barbara J Masten; Gwyneth K Olson; Donna F Kusewitt; Mary F Lipscomb
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

Review 3.  Inflammatory signals in dendritic cell activation and the induction of adaptive immunity.

Authors:  Olivier Joffre; Martijn A Nolte; Roman Spörri; Caetano Reis e Sousa
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

4.  Reversal of long-term sepsis-induced immunosuppression by dendritic cells.

Authors:  Claudia F Benjamim; Steven K Lundy; Nicholas W Lukacs; Cory M Hogaboam; Steven L Kunkel
Journal:  Blood       Date:  2004-12-16       Impact factor: 22.113

5.  Decreasing magnitude of multiple organ dysfunction syndrome despite increasingly severe critical surgical illness: a 17-year longitudinal study.

Authors:  Philip S Barie; Lynn J Hydo; Jian Shou; Soumitra R Eachempati
Journal:  J Trauma       Date:  2008-12

6.  Characterization of the systemic loss of dendritic cells in murine lymph nodes during polymicrobial sepsis.

Authors:  Philip A Efron; Antonio Martins; Douglas Minnich; Kevin Tinsley; Ricardo Ungaro; Frances R Bahjat; Richard Hotchkiss; Michael Clare-Salzler; Lyle L Moldawer
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 7.  Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1996-10-15       Impact factor: 25.391

8.  The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis.

Authors:  Ross L Paterson; Helen F Galley; Nigel R Webster
Journal:  Crit Care Med       Date:  2003-11       Impact factor: 7.598

9.  Cigarette smoke-induced oxidative stress suppresses generation of dendritic cell IL-12 and IL-23 through ERK-dependent pathways.

Authors:  Paula R Kroening; Terrance W Barnes; Larry Pease; Andrew Limper; Hirohito Kita; Robert Vassallo
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  N-acetylcysteine inhibits activation of toll-like receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice.

Authors:  Xin Jin; Lin Wang; He-Shui Wu; Lei Zhang; Chun-You Wang; Yuan Tian; Jing-Hui Zhang
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2007-06
View more
  12 in total

1.  Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury.

Authors:  Jiping Zhao; Hao Yu; Yudong Liu; Sara A Gibson; Zhaoqi Yan; Xin Xu; Amit Gaggar; Pui-Kai Li; Chenglong Li; Shi Wei; Etty N Benveniste; Hongwei Qin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-16       Impact factor: 5.464

2.  Genomic and Genetic Approaches to Deciphering Acute Respiratory Distress Syndrome Risk and Mortality.

Authors:  Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia
Journal:  Antioxid Redox Signal       Date:  2019-06-18       Impact factor: 8.401

Review 3.  Cross-talk between HPA-axis-increased glucocorticoids and mitochondrial stress determines immune responses and clinical manifestations of patients with sepsis.

Authors:  Emiko Kasahara; Masayasu Inoue
Journal:  Redox Rep       Date:  2014-10-13       Impact factor: 4.412

Review 4.  Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.

Authors:  Douglas J Roberts-Wolfe; Peter W Kalivas
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

5.  Protective Effects of Antioxidant Peptide SS-31 Against Multiple Organ Dysfunctions During Endotoxemia.

Authors:  Guoming Li; Jing Wu; Renqi Li; Dong Yuan; Yunxia Fan; Jianjun Yang; Muhuo Ji; Sihai Zhu
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

6.  Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages.

Authors:  Yuanyuan Chen; Guangyan Luo; Jiao Yuan; Yuanyuan Wang; Xiaoqiong Yang; Xiaoyun Wang; Guoping Li; Zhiguang Liu; Nanshan Zhong
Journal:  Mediators Inflamm       Date:  2014-09-01       Impact factor: 4.711

7.  Follistatin-like protein 1 contributes to dendritic cell and T-lymphocyte activation in nasopharyngeal carcinoma patients by altering nuclear factor κb and Jun N-terminal kinase expression.

Authors:  Hong Wang; Senyong Wu; Shiping Huang; Shaolin Yin; Guilong Zou; Kuan'en Huang; Zhe Zhang; Anzhou Tang; Wensheng Wen
Journal:  Cell Biochem Funct       Date:  2016-11-16       Impact factor: 3.685

8.  N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation.

Authors:  Xiao Gao; Eirini-Maria Lampraki; Sarwah Al-Khalidi; Muhammad Asif Qureshi; Rhea Desai; Joanna Beatrice Wilson
Journal:  PLoS One       Date:  2017-12-11       Impact factor: 3.240

9.  N-acetylcysteine tiherapeutically protects against pulmonary fibrosis in a mouse model of silicosis.

Authors:  Huaping Huang; Mingjing Chen; Feng Liu; Haifeng Wu; Jie Wang; Jialiang Chen; Meihua Liu; Xi Li
Journal:  Biosci Rep       Date:  2019-07-18       Impact factor: 3.840

10.  Characterization and Hepatoprotections of Ganoderma lucidum Polysaccharides against Multiple Organ Dysfunction Syndrome in Mice.

Authors:  Yiwen Zhang; Yanbo Feng; Wenshuai Wang; Le Jia; Jianjun Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-02-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.